Stock Track | Moderna Soars 5.53% Intraday on Analyst Upgrades and PDUFA Catalyst

Stock Track

Aug 04

Moderna, Inc. shares surged 5.53% during intraday trading on Tuesday, driven by a confluence of positive catalysts including multiple analyst price target upgrades and heightened anticipation ahead of a critical FDA decision.

The rally was fueled by UBS raising its price target on Moderna from $45 to $50, and Bank of America Global Research increasing its target from $38 to $40, both signaling improving institutional sentiment. Additionally, investors are positioning ahead of the August 5 PDUFA review date for the company's fifth product, Mflusiva, with expectations for approval bolstered by the FDA advisory committee's unanimous 9-0 vote in favor of the seasonal flu vaccine candidate mRNA-1010.

The stock also benefited from Moderna's recent second-quarter results, which showed a narrower-than-expected loss per share of $1.97 and revenue of $145 million, handily beating consensus estimates.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1133093851"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133093851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133093851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133093851","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.53% Intraday on Analyst Upgrades and PDUFA Catalyst","media":"Stock Track","content":"<p>Moderna, Inc. shares surged 5.53% during intraday trading on Tuesday, driven by a confluence of positive catalysts including multiple analyst price target upgrades and heightened anticipation ahead of a critical FDA decision.</p><p>The rally was fueled by UBS raising its price target on Moderna from $45 to $50, and Bank of America Global Research increasing its target from $38 to $40, both signaling improving institutional sentiment. Additionally, investors are positioning ahead of the August 5 PDUFA review date for the company's fifth product, Mflusiva, with expectations for approval bolstered by the FDA advisory committee's unanimous 9-0 vote in favor of the seasonal flu vaccine candidate mRNA-1010.</p><p>The stock also benefited from Moderna's recent second-quarter results, which showed a narrower-than-expected loss per share of $1.97 and revenue of $145 million, handily beating consensus estimates.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.53% Intraday on Analyst Upgrades and PDUFA Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.53% Intraday on Analyst Upgrades and PDUFA Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-04 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. shares surged 5.53% during intraday trading on Tuesday, driven by a confluence of positive catalysts including multiple analyst price target upgrades and heightened anticipation ahead of a critical FDA decision.</p><p>The rally was fueled by UBS raising its price target on Moderna from $45 to $50, and Bank of America Global Research increasing its target from $38 to $40, both signaling improving institutional sentiment. Additionally, investors are positioning ahead of the August 5 PDUFA review date for the company's fifth product, Mflusiva, with expectations for approval bolstered by the FDA advisory committee's unanimous 9-0 vote in favor of the seasonal flu vaccine candidate mRNA-1010.</p><p>The stock also benefited from Moderna's recent second-quarter results, which showed a narrower-than-expected loss per share of $1.97 and revenue of $145 million, handily beating consensus estimates.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1133093851","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133093851","pubTimestamp":1785852463,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. shares surged 5.53% during intraday trading on Tuesday, driven by a confluence of positive catalysts including multiple analyst price target upgrades and heightened anticipation ahead...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票跟踪 | 由于分析师升级和 PDUFA 催化剂，Moderna 盘中飙升 5.53%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. shares surged 5.53% during intraday trading on Tuesday, driven by a confluence of positive catalysts including multiple analyst price target upgrades and heightened anticipation ahead of a critical FDA decision.The rally was fueled by UBS raising its price target on Moderna from $45 to $50, and Bank of America Global Research increasing its target from $38 to $40, both signaling improving institutional sentiment. Additionally, investors are positioning ahead of the August 5 PDUFA review date for the company's fifth product, Mflusiva, with expectations for approval bolstered by the FDA advisory committee's unanimous 9-0 vote in favor of the seasonal flu vaccine candidate mRNA-1010.The stock also benefited from Moderna's recent second-quarter results, which showed a narrower-than-expected loss per share of $1.97 and revenue of $145 million, handily beating consensus estimates.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}